Clinical trials: Dementia Alzheimers
Alzheimer Disease (AD)
Alzheimer's Disease Treated With Vagus Nerve Stimulation
The goal of this clinical trial is to evaluate the safety and efficacy of vagus nerve stimulation (VNS) for treating Alzheimer's disease (AD) in patients aged 50-80 years with mild cognitive impairment to moderate Alzheimer's…
- Trial name
- Advant (NCT06923007)
- Testing
- Vagus Nerve Stimulation
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Amputation, Traumatic, Pain, Phantom
Feasibility of Using an App for Managing Phantom Limb Pain Associated with Combat Injury in Ukraine (PAMELA)
In Ukraine, since the beginning of the full-scale war on February 24, 2022, a large number of individuals have lost a limb(s). Many of these amputees cannot access appropriate care in terms of pain management and rehabilitation.
- Conditions
- Amputation, Traumatic, Pain, Phantom, Pain, Acute, Pain, Chronic
- Trial name
- PAMELA (NCT06604507)
- Testing
- non-pharmacological app
- Where
- 5 sites in Ukraine
- Volunteers
- 200 people
- Sponsor
- Winfried Meißner
Alzheimer s Disease, Mild Cognitive Impairment
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias.
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Trial name
- NCT07169630
- Testing
- 18F-PF974, 18F-florbetaben
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer Disease, Dementia
Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Cognition Disorders
- Trial name
- SUVN-502 (NCT03564964)
- Testing
- SUVN-502
- Sponsor
- Suven Life Sciences Limited
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Biomarkers in Neurodegenerative Diseases
The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD)
- Trial name
- NCT04055532
- Testing
- Neuraceq
- Where
- United States
- Sponsor
- University of Minnesota
Alzheimer Disease
Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells
LO MAPT is an 18-month, phase III, multicenter, randomized, placebo-controlled, 2 parallel groups trial, followed by a 18-month open-label extension phase, to evaluate the efficacy of omega-3 supplementation on cognitive decline…
- Trial name
- LO-MAPT (NCT03691519)
- Testing
- Omega-3 treatment
- Where
- France
- Volunteers
- 774 people
- Sponsor
- University Hospital, Toulouse
Healthy Participants, Healthy Population
Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants
The present study aims to assess the safety and feasibility of repeated transcranial alternating current stimulation (tACS) by the Miamind Neurostimulator in a cohort of healthy participants.
- Trial name
- MindStim (NCT05999916)
- Testing
- Personalized Miamind Neurostimulator
- Where
- Switzerland
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bottneuro AG
Alzheimer Disease and Related Dementias
Promoting Positive Care Interactions (PPCI) in Assisted Living
The overall aim of this study is to pilot test Promoting Positive Care Interactions (PPCI) with the goal of establishing a feasible and culturally responsive approach to optimize care interactions between staff (nursing…
- Trial name
- PPCI (NCT05618834)
- Testing
- Promoting Positive Care Interactions (PPCI), PPCI-Staff Education Only (EO)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Penn State University
Alzheimer's Disease
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with…
- Trial name
- Scarlet Road (NCT01224106)
- Testing
- Gantenerumab
- Where
- 139 sites in United States, Argentina and 22 more
- Volunteers
- 799 people
- Sponsor
- Hoffmann-La Roche
Aging, Alzheimer Disease
The Role of the Locus Coeruleus in Age-related Distractibility
A growing body of research has highlighted the importance of frontal regions, at both the functional and structural levels, in age-related declines in attentional and cognitive processing.
- Trial name
- NCT05574634
- Testing
- Tablet based adaptive multimodal attention practice program, Tablet based adaptive criterion task practice program
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Virginia Polytechnic Institute and State University
Alzheimer's Disease, Lewy Body's Dementia
Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD))
Alzheimer's disease (AD) and Lewy body's dementia (LBD) are two frequent neurodegenerative pathologies. They differ in their expression, their evolution but share same features which make their diagnosis uneasy.
- Trial name
- NCT01993628
- Testing
- Rey figure test, MRI
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Strasbourg, France
Alzheimer Disease
Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation
The investigators will evaluate the theory that Alzheimer's disease-related memory impairment derives from the inefficient orchestration of rhythmic activity at the level of large-scale cortical networks.
- Trial name
- NCT06094192
- Testing
- High definition transcranial electrical current stimulation
- Where
- United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Cerebral Amyloid Angiopathy, Intracranial Hemorrhages
Multimodal Biomarkers for Diagnosis and Prognosis in CAA
By combination of plasma (Aβ40, Aβ42, total tau, and phosphorylated tau, etc.), genetic (ApoE ε2 or ε4 allele), MRI (cerebral perfusion, microbleeds, cortical superficial siderosis, enlarged perivascular space, etc.) and PET…
- Conditions
- Cerebral Amyloid Angiopathy, Intracranial Hemorrhages, Alzheimer Disease
- Trial name
- CAA (NCT03969732)
- Testing
- 1. amyloid PET；2. T807 PET
- Where
- Taiwan
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Down Syndrome (DS)
Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool
Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, is postulated to modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and amyloid beta precursor protein (APP) gene overexpression in…
- Trial name
- NCT01699711
- Testing
- Epigallocatechin-3-gallate (EGCG)
- Where
- Spain
- Volunteers
- 87 people
- Sponsor
- Parc de Salut Mar
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
The primary objective of this open-label extension trial was to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 or ACCORD-2.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
- Trial name
- NCT06736509
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 139 people
- Sponsor
- Axsome Therapeutics, Inc.
Neuropathology, Cognitive Decline
Sleep Impairment in Subjects at Risk of Developing Alzheimer's Disease
Alzheimer's disease (AD) is characterised by a progressive loss of memory and cognitive function. In the early stages of AD, there is a progressive accumulation of molecules: β-amyloid peptides (Aβ) in the brain.
- Conditions
- Neuropathology, Cognitive Decline, Sleep Disorder
- Trial name
- WAVE-APOE4 (NCT05649514)
- Testing
- Polysomnography, Neuropsychological assessment, Questionnaires on sleep and behavioural problems
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Montpellier
Mild to Moderate Alzheimer's Disease
Study of LM11A-31-BHS in Mild-moderate AD Patients
The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180 patients with Alzheimer's Disease versus placebo and to access biomarker and clinical exploratory endpoints of LM11A-31-BHS
- Trial name
- NCT03069014
- Testing
- 400mg LM11A-31-BHS, 800mg LM11A-31-BHS
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 242 people
- Sponsor
- PharmatrophiX Inc.
Cognitive Impairment, Alzheimer Disease
Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen
The clinical evaluation of a patient with a cognitive complaint requires neuropsychological tests, evaluating the integrity of memory and other cognitive functions.
- Trial name
- MemScreen (NCT03811184)
- Testing
- MemScreen
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MemScreen
Alzheimer Disease, Mild Cognitive Impairment
The COMFORTage Project at Ace Alzheimer Center Barcelona
The COMFORTage study at Ace Alzheimer Center Barcelona is investigating whether a personalized cognitive and functional stimulation program can help slow cognitive decline in individuals diagnosed with mild cognitive impairment…
- Trial name
- COMFORTage (NCT07031167)
- Testing
- Cognitive and functional stimulation using digital platforms
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Fundació ACE Institut Català de Neurociències Aplicades
Down Syndrome, Alzheimer's Disease
Down Syndrome Biomarker Initiative (DSBI)
Non-randomized natural history study involving 12 subjects with Down Syndrome, who are aged 30-60 years old. This study will observe 3 different groups: four non-demented subjects between ages 30-40 years old, four non-demented…
- Trial name
- DSBI (NCT02141971)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Michael Rafii
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.